-
1.
公开(公告)号:US20240318188A1
公开(公告)日:2024-09-26
申请号:US18572827
申请日:2022-06-24
申请人: BASF SE
摘要: The present invention relates to a Bacillus licheniformis host cell for production of biological compounds with increased purity. Specifically, the invention relates to a Bacillus licheniformis host with one or more genetic modifications selected from a) a genetic modification causing compared to an unmodified control cell an increased expression of at least one of the genes selected from the group consisting of degQ, degll, degS, degR, and phrG, b) a genetic modification causing compared to an unmodified control cell an increased autophosphorylation activity of the DegS protein, and c) a genetic modification causing compared to an unmodified control cell a reduced phosphatase activity of the DegS protein. The present invention further relates to a method for production of at least one compound of interest with increased purity based on cultivating the bacterial host cell of the present invention.
-
2.
公开(公告)号:US20240316122A1
公开(公告)日:2024-09-26
申请号:US18271714
申请日:2022-01-11
发明人: Anna Sokolovska , Aoife Brennan
IPC分类号: A61K35/741 , A61K39/00 , A61K39/395 , C07K16/28 , C12N1/20 , C12N9/48 , C12R1/19
CPC分类号: A61K35/741 , A61K39/3955 , C07K16/2827 , C12N1/205 , C12N9/485 , C12Y304/16004 , A61K2039/505 , A61K2039/545 , C12R2001/19
摘要: Therapies comprising a recombinant microorganism expressing a STING agonist, and methods of modulating and treating cancers are disclosed.
-
公开(公告)号:US12091693B2
公开(公告)日:2024-09-17
申请号:US17497085
申请日:2021-10-08
IPC分类号: C12N9/48 , A61K31/454 , A61K31/4745 , A61K31/475 , A61K38/00 , A61K47/54 , A61K49/00 , A61K51/04 , C12N9/96
CPC分类号: C12N9/485 , A61K31/454 , A61K31/4745 , A61K31/475 , A61K47/542 , A61K49/0032 , A61K49/0052 , A61K51/0402 , A61K51/0497 , C12N9/96 , A61K38/00 , C12Y304/17021
摘要: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical compositions containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
-
公开(公告)号:US20240254468A1
公开(公告)日:2024-08-01
申请号:US18587167
申请日:2024-02-26
发明人: Trisha Barrett , Aaron Argyros
CPC分类号: C12N9/2402 , C12N1/18 , C12N9/1051 , C12N9/2405 , C12N9/48 , C12P7/10 , C12Y204/01001 , C12Y302/01028
摘要: The present disclosure concerns a recombinant yeast host cell exhibiting higher stability and, in some embodiments, higher fermentation performance. The recombinant yeast host cell stability has a limited ability to express an hydrolase during its propagation phase. In return, this limits the cleavage of a yeast cellular component during or after propagation which may be detrimental to the stability and/or fermentation performances. The recombinant yeast host cell expresses a heterologous hydrolase under the control of a heterologous promoter (for limiting the expression of the heterologous hydrolase during propagation and favoring the expression of the heterologous hydrolase during fermentation).
-
公开(公告)号:US20240240167A1
公开(公告)日:2024-07-18
申请号:US18618330
申请日:2024-03-27
申请人: AJINOMOTO CO., INC.
发明人: Mizuki Tamori , Uno Tagami , Hiroyuki Nozaki
摘要: Described herein is an enzyme useful for producing a target peptide, capable of producing the target peptide without requiring ATP. More specifically, provided herein is a modified enzyme includes an amino acid sequence such as a modified amino acid sequence including a mutation of one or more of the following amino acid residues: E81, I127, I136, T139, F140, G142, W143, I147, I181, I201, Q219, T229, M244, A249, P255, E256, I260, S293, N294, Y295, and I299 in an amino acid sequence of SEQ ID NO: 1, and
having the following property (a) or (b) enhanced relative to an enzyme of the amino acid sequence of SEQ ID NO: 1:
(a) imidazole dipeptide production activity; or
(b) thermal stability.-
公开(公告)号:US12031163B2
公开(公告)日:2024-07-09
申请号:US16062330
申请日:2016-12-16
申请人: BASF Enzymes LLC
发明人: Yun Han
IPC分类号: C12N9/26 , C09K8/00 , C09K8/58 , C11D3/386 , C12N9/16 , C12N9/24 , C12N9/34 , C12N9/42 , C12N9/48 , C12N9/50 , C12N9/96 , C12P19/14
CPC分类号: C12N9/2414 , C09K8/00 , C09K8/58 , C11D3/38618 , C11D3/38663 , C11D3/38681 , C12N9/16 , C12N9/2425 , C12N9/2428 , C12N9/2437 , C12N9/2445 , C12N9/248 , C12N9/2488 , C12N9/485 , C12N9/50 , C12N9/96 , C12P19/14 , C12Y302/01001 , C12Y302/01002 , C12Y302/01003 , C12Y302/01008 , C12Y302/01021 , C12Y302/01025 , C12Y302/01041
摘要: The present disclosure relates to liquid enzyme formulations containing one or more alpha-amylases for use in starch processing, wherein the pH of the enzyme formulation is about pH 6.0-8.0, and methods of use thereof. The present disclosure further relates to methods of making a liquid enzyme formulation containing one or more alpha-amylase having improved stability, comprising titrating the pH of the liquid enzyme formulation to a range of pH 6.0-8.0.
-
公开(公告)号:US20240209311A1
公开(公告)日:2024-06-27
申请号:US18432964
申请日:2024-02-05
摘要: This invention concerns a method for preparing a bacterial supernatant comprising culturing a cell of Pseudomonas environmental strain PF-11; and recovering the supernatant. This invention also concerns a method for reducing the amount of a biofilm on a surface, reducing adhesion of at least one organism to a surface, or reducing microfouling or macrofouling on a surface comprising contacting the surface with a supernatant, supernatant fraction, modified supernatant or modified supernatant fraction of Pseudomonas strain PF-11; or a composition comprising a supernatant, supernatant fraction, modified supernatant or modified supernatant fraction of Pseudomonas strain PF-11, and one or more acceptable carriers. This invention also concerns a method for killing or reducing the growth of a fungus or bacterial cell, or killing or inhibiting the development of an insect or marine copepod, comprising contacting the fungus, bacteria, insect or marine copepod with a supernatant, supernatant fraction, modified supernatant or modified supernatant fraction of a Pseudomonas strain PF-11 culture; or a composition comprising a supernatant, supernatant fraction, modified supernatant or modified supernatant fraction of a Pseudomonas strain PF-11 culture, and one or more acceptable carriers. This invention also concerns a substantially pure culture of Pseudomonas strain PF-11. This invention also concerns a culture that is enriched in Pseudomonas strain PF-11. This invention also provides a method of identifying whether a bacteria is capable of producing one or more extracellular proteases capable of digesting a high molecular weight substrate.
-
公开(公告)号:US12011466B2
公开(公告)日:2024-06-18
申请号:US17625220
申请日:2020-07-07
申请人: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ TOULOUSE III—PAUL SABATIER , ECOLE NATIONALE VÉTÉRINAIRE DE TOULOUSE , INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) , CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
IPC分类号: A61K35/741 , A61P1/00 , C12N1/20 , C12N9/48 , C12R1/19
CPC分类号: A61K35/741 , A61P1/00 , C12N1/205 , C12N9/485 , C12R2001/19
摘要: The invention relates to the field of modified Escherichia coli strain Nissle 1917 (EcN) and its use for treating gastro-intestinal disorders. The invention is based on the study of the mechanisms implicated in the probiotic properties of the Escherichia coli strain Nissle 1917 (EcN). This study has allowed the inventors to decouple the probiotic activity of EcN from its genotoxic activity by demonstrating that EcN ClbP protein, the enzyme that activates the genotoxin colibactin, is also required for the siderophore-microcins activity of probiotic EcN, but interestingly, not its enzymatic domain that cleaves precolibactin to form active colibactin. Furthermore, inventors demonstrate in an in vivo animal model infected by a bacterial pathogen that administration of an EcN modified strain with clbP gene encoding ClbP protein inactive for the peptidase domain, is non-genotoxic (do not produce colibactin) but keeps the bacterial antagonist activity, and reduces colonization and virulence of the pathogen by maintaining the siderophore-microcin production. Thus this study opens the way to safe use of EcN and accordingly the present invention provides an Escherichia coli strain Nissle 1917 (EcN) bacterium carrying a gene encoding ClbP protein which is inactive for the peptidase domain, and its use as a drug and more particularly for use in the treatment of gastro-intestinal disease.
-
公开(公告)号:US20240191219A1
公开(公告)日:2024-06-13
申请号:US18411153
申请日:2024-01-12
申请人: BASF Enzymes LLC
发明人: Yun Han
IPC分类号: C12N9/26 , C11D3/386 , C12N9/16 , C12N9/24 , C12N9/34 , C12N9/42 , C12N9/48 , C12N9/50 , C12N9/96 , C12P19/14
CPC分类号: C12N9/2414 , C11D3/38618 , C11D3/38663 , C11D3/38681 , C12N9/16 , C12N9/2425 , C12N9/2428 , C12N9/2437 , C12N9/2445 , C12N9/248 , C12N9/2488 , C12N9/485 , C12N9/50 , C12N9/96 , C12P19/14 , C12Y302/01001 , C12Y302/01002 , C12Y302/01003 , C12Y302/01008 , C12Y302/01021 , C12Y302/01025 , C12Y302/01041
摘要: The present disclosure relates to liquid enzyme formulations containing one or more alpha-amylases for use in starch processing, wherein the pH of the enzyme formulation is about pH 6.0-8.0, and methods of use thereof. The present disclosure further relates to methods of making a liquid enzyme formulation containing one or more alpha-amylase having improved stability, comprising titrating the pH of the liquid enzyme formulation to a range of pH 6.0-8.0.
-
公开(公告)号:US20240190935A1
公开(公告)日:2024-06-13
申请号:US18285320
申请日:2022-04-25
发明人: Mark David Mannie
IPC分类号: C07K14/565 , C07K16/10 , C12N9/48
CPC分类号: C07K14/565 , C07K16/1003 , C12N9/485 , C12Y304/17023
摘要: The present inventive concept provides a therapeutic platform that will prevent disease and reverse disease morbidity and mortality wherein the causative agent is a member of a broad class of infectious disease agents that mediate pathogenesis via mechanisms that are ameliorated by an interferon. The platform is based on the construction of single-chain soluble fusion proteins including a pathogen recognition domain, a linker and a pathogenesis-inhibiting effector domain.
-
-
-
-
-
-
-
-
-